L2, the minor capsid protein of papillomavirus. PMID: 23689062
Human Papillomavirus Minor Capsid Protein L2 Mediates Intracellular Trafficking into and Passage beyond the Endoplasmic Reticulum. PMID: 35608352
Genetic variability in minor capsid protein (L2 gene) of human papillomavirus type 16 among Indian women. PMID: 35552511
Insights into the role and function of L2, the minor capsid protein of papillomaviruses. PMID: 19169853
Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses. PMID: 29212932
Subcellular Trafficking of the Papillomavirus Genome during Initial Infection: The Remarkable Abilities of Minor Capsid Protein L2. PMID: 29207511
Human Papillomavirus L2 Capsid Protein Stabilizes γ-Secretase during Viral Infection. PMID: 35458534
Topography of the Human Papillomavirus Minor Capsid Protein L2 during Vesicular Trafficking of Infectious Entry. PMID: 26246568
Modification of human papillomavirus minor capsid protein L2 by sumoylation. PMID: 20739540
Antibody Competition Reveals Surface Location of HPV L2 Minor Capsid Protein Residues 17-36. PMID: 29125554
Human papillomavirus 16 minor capsid protein L2 helps capsomeres assemble independently of intercapsomeric disulfide bonding. PMID: 16175337
Refolding and in vitro characterization of human papillomavirus 16 minor capsid protein L2. PMID: 30375341
Efficient Inhibition of Human Papillomavirus Infection by L2 Minor Capsid-Derived Lipopeptide. PMID: 31387913
High resolution cryo EM analysis of HPV16 identifies minor structural protein L2 and describes capsid flexibility. PMID: 33568731
Human papillomavirus type 16 minor capsid protein l2 N-terminal region containing a common neutralization epitope binds to the cell surface and enters the cytoplasm. PMID: 11160736
The minor capsid protein L2 contributes to two steps in the human papillomavirus type 31 life cycle. PMID: 15767396
Production and characterization of virus-like particles of grapevine fanleaf virus presenting L2 epitope of human papillomavirus minor capsid protein. PMID: 31752839
The l2 minor capsid protein of human papillomavirus type 16 interacts with a network of nuclear import receptors. PMID: 15507604
Nuclear translocation of papillomavirus minor capsid protein L2 requires Hsc70. PMID: 15140951
Recombinant Viral Capsid Protein L2 (rVL2) of HPV 16 Suppresses Cell Proliferation and Glucose Metabolism via ITGB7/C/EBPβ Signaling Pathway in Cervical Cancer Cell Lines. PMID: 31819523
Nuclear localization but not PML protein is required for incorporation of the papillomavirus minor capsid protein L2 into virus-like particles. PMID: 14722267
The papillomavirus minor capsid protein, L2, induces localization of the major capsid protein, L1, and the viral transcription/replication protein, E2, to PML oncogenic domains. PMID: 9420209
Direct binding of retromer to human papillomavirus type 16 minor capsid protein L2 mediates endosome exit during viral infection. PMID: 25693203
Conformational and linear epitopes on virus-like particles of human papillomavirus type 33 identified by monoclonal antibodies to the minor capsid protein L2. PMID: 7595373
Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16. PMID: 12857908
Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2. PMID: 26003490
The high risk HPV16 L2 minor capsid protein has multiple transport signals that mediate its nucleocytoplasmic traffic. PMID: 22154072
A surface immunodeterminant of human papillomavirus type 16 minor capsid protein L2. PMID: 9636375
Nuclear location of minor capsid protein L2 is required for expression of a reporter plasmid packaged in HPV51 pseudovirions. PMID: 19766281
Identification of a dynein interacting domain in the papillomavirus minor capsid protein l2. PMID: 16775357
Prophylactic papillomavirus vaccines. PMID: 24559559
Master mitotic kinases regulate viral genome delivery during papillomavirus cell entry. PMID: 36683055
Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2. PMID: 22961598
Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today? PMID: 31877975
Expression pattern and subcellular localization of human papillomavirus minor capsid protein L2. PMID: 19095951
Cleavage of the HPV16 Minor Capsid Protein L2 during Virion Morphogenesis Ablates the Requirement for Cellular Furin during De Novo Infection. PMID: 26569287
Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach. PMID: 26362430
Nuclear import strategies of high-risk HPV18 L2 minor capsid protein. PMID: 16733063
A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2. PMID: 21858066
Arrangement of L2 within the papillomavirus capsid. PMID: 18367526
Host cell transcriptome modification upon exogenous HPV16 L2 protein expression. PMID: 29207600
The positively charged termini of L2 minor capsid protein required for bovine papillomavirus infection function separately in nuclear import and DNA binding. PMID: 15564455
Human Papillomavirus Major Capsid Protein L1 Remains Associated with the Incoming Viral Genome throughout the Entry Process. PMID: 28566382
A membrane-destabilizing peptide in capsid protein L2 is required for egress of papillomavirus genomes from endosomes. PMID: 16378978
The l2 minor capsid protein of low-risk human papillomavirus type 11 interacts with host nuclear import receptors and viral DNA. PMID: 16873281
Critical Residues Involved in the Coassembly of L1 and L2 Capsid Proteins of Human Papillomavirus 16. PMID: 36815785
Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. PMID: 16432208
The Cytoskeletal Adaptor Obscurin-Like 1 Interacts with the Human Papillomavirus 16 (HPV16) Capsid Protein L2 and Is Required for HPV16 Endocytosis. PMID: 27654294
Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein. PMID: 12208958
Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6. PMID: 10364381
A central region in the minor capsid protein of papillomaviruses facilitates viral genome tethering and membrane penetration for mitotic nuclear entry. PMID: 28464022
Factors influencing subcellular localization of the human papillomavirus L2 minor structural protein. PMID: 16257028
Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection. PMID: 19421199
Interaction of the papillomavirus transcription/replication factor, E2, and the viral capsid protein, L2. PMID: 11040122
Progress and prospects for L2-based human papillomavirus vaccines. PMID: 26901354
Reorganization of nuclear domain 10 induced by papillomavirus capsid protein l2. PMID: 12033769
Monoclonal antibodies recognizing cross-neutralization epitopes in human papillomavirus 16 minor capsid protein L2. PMID: 23051711
Cyclophilins facilitate dissociation of the human papillomavirus type 16 capsid protein L1 from the L2/DNA complex following virus entry. PMID: 22761365
Optimized production strategy of the major capsid protein HPV 16L1 non-assembly variant in E. coli. PMID: 32681956
Assembly of the major and the minor capsid protein of human papillomavirus type 33 into virus-like particles and tubular structures in insect cells. PMID: 8178438
RG1-VLP and Other L2-Based, Broad-Spectrum HPV Vaccine Candidates. PMID: 33802456
Cell-Free Expression of HPV16 Minor Capsid Protein L2 and Its Interaction with S100A10., PMID:40415288
TAGLN2-mediated Actin Cytoskeleton Stabilization Promotes Proliferation and Metastasis of Ovarian Carcinoma., PMID:40247723
HPV16 entry requires dynein for minus-end transport and utilizes kinesin Kif11 for plus-end transport along microtubules during mitosis., PMID:39629998
Glycan-induced structural activation softens the human papillomavirus capsid for entry through reduction of intercapsomere flexibility., PMID:39572555
Rab6a enables BICD2/dynein-mediated trafficking of human papillomavirus from the trans-Golgi network during virus entry., PMID:39431827
Immunoinformatics approach for design novel multi-epitope prophylactic and therapeutic vaccine based on capsid proteins L1 and L2 and oncoproteins E6 and E7 of human papillomavirus 16 and human papillomavirus 18 against cervical cancer., PMID:39039819
A peptide derived from sorting nexin 1 inhibits HPV16 entry, retrograde trafficking, and L2 membrane spanning., PMID:38909779
The BICD2 dynein cargo adaptor binds to the HPV16 L2 capsid protein and promotes HPV infection., PMID:38829892
A Peptide Derived from Sorting Nexin 1 Inhibits HPV16 Entry, Retrograde Trafficking, and L2 Membrane Spanning., PMID:38826391
Advances on two serological assays for human papillomavirus provide insights on the reactivity of antibodies against a cross-neutralization epitope of the minor capsid protein L2., PMID:38022617
Sequence-independent activity of a predicted long disordered segment of the human papillomavirus type 16 L2 capsid protein during virus entry., PMID:37819982
Alum and a TLR7 agonist combined with built-in TLR4 and 5 agonists synergistically enhance immune responses against HPV RG1 epitope., PMID:37798448
Crystal Structures of Plk1 Polo-Box Domain Bound to the Human Papillomavirus Minor Capsid Protein L2-Derived Peptide., PMID:37684534
Sequence independent activity of a predicted long disordered segment of the human papillomavirus L2 capsid protein during virus entry., PMID:36993745
Critical Residues Involved in the Coassembly of L1 and L2 Capsid Proteins of Human Papillomavirus 16., PMID:36815785
Mutation Profile of HPV16 L1 and L2 Genes in Different Geographic Areas., PMID:36680181
Next generation L2-based HPV vaccines cross-protect against cutaneous papillomavirus infection and tumor development., PMID:36263027
Detection of HPV16 viral load in L2 gene as a related predictor of cervical cancer among women in Dhi-Qar province by qRT-PCR., PMID:36214947
HPV16 Induces Formation of Virus-p62-PML Hybrid Bodies to Enable Infection., PMID:35891458
Human Papillomavirus Type 16 L2 Gene Sequence Variation Analysis in Indonesian Cervical Cancer Specimens., PMID:35763643
RG2-VLP: a Vaccine Designed to Broadly Protect against Anogenital and Skin Human Papillomaviruses Causing Human Cancer., PMID:35703545
Human Papillomavirus Minor Capsid Protein L2 Mediates Intracellular Trafficking into and Passage beyond the Endoplasmic Reticulum., PMID:35608352
Genetic variability in minor capsid protein (L2 gene) of human papillomavirus type 16 among Indian women., PMID:35552511
Human Papillomavirus L2 Capsid Protein Stabilizes γ-Secretase during Viral Infection., PMID:35458534
Dissolving Microneedle Delivery of a Prophylactic HPV Vaccine., PMID:35139303
HPV16 Entry into Epithelial Cells: Running a Gauntlet., PMID:34960729
Identification of heterogenous nuclear ribonucleoproteins (hnRNPs) and serine- and arginine-rich (SR) proteins that induce human papillomavirus type 16 late gene expression and alter L1 mRNA splicing., PMID:34860285
A respirable HPV-L2 dry-powder vaccine with GLA as amphiphilic lubricant and immune-adjuvant., PMID:34740725
Cryo EM Analysis Reveals Inherent Flexibility of Authentic Murine Papillomavirus Capsids., PMID:34696452
Designing a therapeutic and prophylactic candidate vaccine against human papillomavirus through vaccinomics approaches., PMID:34547435
Immunological responses and anti-tumor effects of HPV16/18 L1-L2-E7 multiepitope fusion construct along with curcumin and nanocurcumin in C57BL/6 mouse model., PMID:34516991
In Silico Design and Immunological Studies of Two Novel Multiepitope DNA-Based Vaccine Candidates Against High-Risk Human Papillomaviruses., PMID:34308516
Mutation Profiles, Glycosylation Site Distribution and Codon Usage Bias of Human Papillomavirus Type 16., PMID:34209097
Computational Modeling of Immune Response Triggering Immunogenic Peptide Vaccine Against the Human Papillomaviruses to Induce Immunity Against Cervical Cancer., PMID:33973819
RG1-VLP and Other L2-Based, Broad-Spectrum HPV Vaccine Candidates., PMID:33802456
Human Papillomavirus infection requires the CCT Chaperonin Complex., PMID:33731457
Improvement of RG1-VLP vaccine performance in BALB/c mice by substitution of alhydrogel with the next generation polyphosphazene adjuvant PCEP., PMID:33573433
High resolution cryo EM analysis of HPV16 identifies minor structural protein L2 and describes capsid flexibility., PMID:33568731
A Scalable Manufacturing Approach to Single Dose Vaccination against HPV., PMID:33478147
Optimization of RG1-VLP vaccine performance in mice with novel TLR4 agonists., PMID:33309485
Human Papillomavirus 16 L2 Recruits both Retromer and Retriever Complexes during Retrograde Trafficking of the Viral Genome to the Cell Nucleus., PMID:33177206
Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes., PMID:32967963
Optimized production strategy of the major capsid protein HPV 16L1 non-assembly variant in E. coli., PMID:32681956
Correlation between cervical HPV DNA detection and HPV16 seroreactivity measured with L1-only and L1+L2 viral capsid antigens., PMID:32510304
The possible regions to design Human Papilloma Viruses vaccine in Iranian L1 protein., PMID:32435064
Cell-penetrating peptide inhibits retromer-mediated human papillomavirus trafficking during virus entry., PMID:32123072
Recombinant Viral Capsid Protein L2 (rVL2) of HPV 16 Suppresses Cell Proliferation and Glucose Metabolism via ITGB7/C/EBPβ Signaling Pathway in Cervical Cancer Cell Lines., PMID:31819523
Glutathione contributes to efficient post-Golgi trafficking of incoming HPV16 genome., PMID:31743367
Production and Preliminary In Vivo Evaluations of a Novel in silico-designed L2-based Potential HPV Vaccine., PMID:31729940
In silico/In vivo analysis of high-risk papillomavirus L1 and L2 conserved sequences for development of cross-subtype prophylactic vaccine., PMID:31645650
For research use only. Not for human or drug use.
